AZ 191

Pricing Availability Delivery Time Qty
Cat.No. 5232 - AZ 191 | C24H27N7O | CAS No. 1594092-37-1
Description: Potent DYRK1B inhibitor
Chemical Name: N-[2-Methoxy-4-(4-methyl-1-piperazinyl)phenyl]-4-(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-pyrimidinamine
Purity: ≥98% (HPLC)
Datasheet
Citations
Literature

Biological Activity

Potent DYRK1B inhibitor (IC50 values are 17, 88 and 1890 nM for DYRK1B, DYRK1A and DYRK2 respectively). Inhibits DYRK1B-induced Gi phase cell cycle arrest in Panc-1 cells in vitro.

External Portal Information

Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of AZ 191 is reviewed on the chemical probes website.

Compound Libraries

AZ 191 is also offered as part of the Tocriscreen Plus and Tocriscreen Kinase Inhibitor Toolbox II. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 429.52
Formula C24H27N7O
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1594092-37-1
PubChem ID 72716071
InChI Key ZYVXTMKTGDARKR-UHFFFAOYSA-N
Smiles CN2C=C(C3=CC=NC(NC4=C(OC)C=C(N5CCN(C)CC5)C=C4)=N3)C1=CC=NC=C12

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 42.95 100
ethanol 8.59 20

Preparing Stock Solutions

The following data is based on the product molecular weight 429.52. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.33 mL 11.64 mL 23.28 mL
5 mM 0.47 mL 2.33 mL 4.66 mL
10 mM 0.23 mL 1.16 mL 2.33 mL
50 mM 0.05 mL 0.23 mL 0.47 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Safety Datasheet

References

References are publications that support the products' biological activity.

Ashford et al (2014) A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3 beta to phosphorylate cyclin D1 at Thr(286), not Thr(288). Biochem.J. 457 43 PMID: 24134204


If you know of a relevant reference for AZ 191, please let us know.

View Related Products by Target

View Related Products by Product Action

View all DYRK Inhibitors

Keywords: AZ191 potent dyrk1b dual specificity tyrosine phosphorylation regulated kinases inhibitors inhibits DYRK

Citations for AZ 191

Citations are publications that use Tocris products.

Currently there are no citations for AZ 191. Do you know of a great paper that uses AZ 191 from Tocris? If so please let us know.

Commented out for usability testing

Reviews

TODO: Add Reviews

Literature in this Area

Kinases

Kinases Product Listing

A collection of over 400 products for kinase research, the listing includes inhibitors of:

  • Receptor Tyrosine Kinases
  • Protein Kinases A, C, D and G
  • PI-3 Kinase, Akt and mTOR
  • MAPK Signaling
  • Receptor Serine/Threonine Kinases
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Alzheimer's

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Pathways for AZ 191

Protocols

TODO: Add Protocols